© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
May 27, 2021
The FDA has approved the PSMA PET imaging agent 18F-DCFPyL for use in prostate cancer.
May 24, 2021
Jason Zhu, MD, discusses how next-generation imaging is critical to advancing personalized medicine in prostate cancer.
May 18, 2021
18F-fluciclovine-PET/CT imaging led to improved outcomes with postprostatectomy salvage radiotherapy versus conventional imaging.
May 05, 2021
The SECURE trial is exploring the PSMA PET imaging product 64Cu-SAR-bisPSMA and the PSMA targeted therapy 67Cu-SAR-bisPSMA.
April 14, 2021
The PSMA-targeted radiopharmaceutical 177Lu-PSMA-617 is poised to become one of the first PSMA theranostics approved by the FDA.
April 02, 2021
Tagawa draws specific attention to the targeted radioligand therapy 177Lu-PSMA-617.
March 23, 2021
The targeted radioligand therapy 177Lu-PSMA-617 also improved progression-free survival when added to best standard of care (BSC) compared with BSC alone.
March 16, 2021
At the New York GU 14th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Phillip J. Koo, MD, highlighted the potential of next-generation imaging to revolutionize the management of patients with prostate cancer.
March 15, 2021
PSA response rate was higher with the investigational radioligand therapy.
March 02, 2021
The FDA is currently reviewing the results of these trials and is scheduled to make an approval decision by May 28, 2021.